menu
    • menu
    [{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laxxon Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Undisclosed"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Laxxon Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Undisclosed"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Laxxon Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Undisclosed"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Adare Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laxxon Medical \/ Laxxon Medical","highestDevelopmentStatusID":"2","companyTruncated":"Laxxon Medical \/ Laxxon Medical"}]

    Find Clinical Drug Pipeline Developments & Deals by Laxxon Medical

    Menu

    Laxxon Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laxxon’s LXM.5 Shows Positive Pilot PK Results for Parkinson’s Disease

                            Details : A new generation levodopa/carbidopa asset LXM.5 is being developed for the treatment of patients with parkinson's disease (PD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LXM.2

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laxxon Medical Reports Positive PK Study Results for Oral GLP-1 Dosage

                            Details : LXM.2 is an once-daily oral, first-in-class GLP-1 agonist, currently being investigated for diabetes, metabolic syndrome and weight loss.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : LXM.2

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Adare Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms

                            Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Adare Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Laxxon Medical

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LXM.2

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laxxon Medical Develops Non-Invasive 3D Printed Oral GLP-1 Therapy

                            Details : LXM.2 is a 3D printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2024

                            Lead Product(s) : LXM.2

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth